Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Hinyokika Kiyo ; 57(1): 7-13, 2011 Jan.
Artigo em Japonês | MEDLINE | ID: mdl-21304253

RESUMO

A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50 mg of naftopidil was given once a day after breakfast or supper for 8 weeks. Data were available for efficacy analysis on 80 patients (M group ; 43, E group ; 37). Naftopidil significantly improved the overall international prostatic symptom score ; from 19.2±7.9 to 11.7±5.8 in the M group and from 19.4±6.4 to 12.3±6.8 in the E group (p<0.0001), QOL score from 4.9±0.8 to 3.2±1.4 in the M group and from 5.0±0.8 to 3.6±1.3 in the E group (p<0.0001), and OAB symptom score from 7.8±2.6 to 5.0±2.5 in the M group (p<0.0001) and from 8.6±2.9 to 5.8± 3.3 in the E group (p<0.0001). There was no significant difference in the incidence of adverse effects between the M group (6.1%) and E group (2.2%). These results suggest that naftopidil improves storage symptoms as well as voiding symptoms regardless of timing of administration.


Assuntos
Antagonistas Adrenérgicos alfa/administração & dosagem , Naftalenos/administração & dosagem , Piperazinas/administração & dosagem , Hiperplasia Prostática/tratamento farmacológico , Bexiga Urinária Hiperativa/tratamento farmacológico , Antagonistas Adrenérgicos alfa/efeitos adversos , Idoso , Idoso de 80 Anos ou mais , Esquema de Medicação , Humanos , Masculino , Pessoa de Meia-Idade , Naftalenos/efeitos adversos , Piperazinas/efeitos adversos , Hiperplasia Prostática/complicações , Bexiga Urinária Hiperativa/etiologia
2.
Hinyokika Kiyo ; 48(5): 259-67, 2002 May.
Artigo em Japonês | MEDLINE | ID: mdl-12094707

RESUMO

We evaluated the clinical efficacy and safety of tamsulosin hydrochloride and cernitin pollen extract in 243 patients with urinary disturbance associated with benign prostatic hyperplasia. They were assigned randomly to 3 groups, oral tamsulosin hydrochloride, cernitin pollen extract and their combination were administered for 12 weeks. The international prostate symptom score, post-voided residual urine and uroflowmetrogram were obtained before and after treatment. The international prostate symptom score improved in each group and then the maximum flow rate and average flow rate also increased significantly in the tamsulosin hydrochloride-administered groups. In conclusion, the administration of only tamsulosin hydrochloride and the combination of tamsulosin hydrochloride and cernitin pollen extract seemed more effective then the administration of only cernitin pollen extract in the treatment of urinary disturbance associated with benign prostatic hyperplasia.


Assuntos
Antagonistas Adrenérgicos alfa/uso terapêutico , Extratos Vegetais/uso terapêutico , Hiperplasia Prostática/complicações , Sulfonamidas/uso terapêutico , Transtornos Urinários/tratamento farmacológico , Idoso , Esquema de Medicação , Quimioterapia Combinada , Humanos , Masculino , Pessoa de Meia-Idade , Secale , Tansulosina , Transtornos Urinários/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...